Results 261 to 270 of about 89,572 (287)

Docetaxel

Reactions Weekly, 2019
openaire   +2 more sources

Nanoways to overcome docetaxel resistance in prostate cancer

Drug Resistance Updates, 2014
Aditya Ganju, Murali M Yallapu, Sheema Khan   +2 more
exaly  

Docetaxel

Reactions Weekly, 2017
openaire   +2 more sources

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Annals of Oncology, 2012
C Pezaro, D Bianchini, A Zivi
exaly  

Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation

Journal of Controlled Release, 2009
Fu-De Cui, Suk-Jae Chung, Chang-Koo Shim   +2 more
exaly  

A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer

Annals of Oncology, 2004
Kei Muro, T Hamaguchi, Atsushi Ohtsu
exaly  

Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy

Biomaterials, 2013
Allison N Schorzman, Andrew J Madden, Andrew Z Wang   +2 more
exaly  

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

European Journal of Cancer, 2010
Yohann Loriot, Marine Gross-Goupil, Mario Di Palma   +2 more
exaly  

Docetaxel

Reactions Weekly, 2023
openaire   +1 more source

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

Annals of Oncology, 2015
S-E Al-Batran, R -D Hofheinz, A Hinke
exaly